Project Grant R43DA061909
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$398K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,483 to Jillion Therapeutics Inc. to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for the treatment of substance use disorders (SUDs). The key objectives are to: 1) Screen a DEL of 125 million compounds plus an additional 1 million GPCR-focused compounds...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...
This Project Grant award of $399,536 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research by Chemregen Inc. to design, synthesize, and test non-opioid drug candidates as a new approach to combat the opioid crisis. The key objectives are to: 1) Design and synthesize lead and control compounds, characterize them chemically and pharmacologically for receptor binding, and conduct ADMET studies; and 2) Characterize human...
This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The grantee, Boston Interactome LLC, will apply a mammalian cell-based compound screening platform to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression under chronic opioid exposure. The efficacy and specificity of the...
This Project Grant award of $571,675 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a forward genetic screen to identify novel genes involved in the mechanism of action of the addictive drug amphetamine. The research will be conducted by Florida Atlantic University, a Hispanic-serving institution with extensive federal research and contracting experience. The objective is to use the Million Mutations Project (MMP)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,230.00 to Rafias LLC located in Philadelphia, PA. The funding supports research to advance NR4A1 as a novel target for treating cocaine use disorder. Key objectives include: 1) Lead identification by synthesizing and screening CsnB derivatives that activate human/mouse NR4A1, and 2) Lead optimization by characterizing lead compound(s) using...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The $397,829 award to Callentis Consulting Group LLC, a woman-owned small business, will fund the creation of curated training datasets, machine learning models, and identification of mechanistic targets related to the glucagon-like peptide 1 (GLP-1)...
This $3,287,052 Cooperative Agreement (UG3DA061709) awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports Virogenomics Biodevelopment, Inc., a woman-owned small business, in conducting IND-enabling studies and Phase I clinical trials to advance DRHQ, an immunotherapeutic compound targeting CD74 receptors, as a potential treatment for methamphetamine use disorder. The key products and services to be delivered under this...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $798,828 to Dark Matter Therapeutics, Inc. to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The project aims to leverage artificial intelligence (AI) to develop a drug discovery strategy that integrates target-based and phenotype-based methodologies. Specifically, the AI platform M3.AI...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing new treatments for opioid use disorder. The $1,717,200 award, spanning August 1, 2024 to May 31, 2029, will enable researchers at the University of...